# A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

> **NCT01649336** · PHASE1 · COMPLETED · sponsor: **Array Biopharma, now a wholly owned subsidiary of Pfizer** · enrollment: 36 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** MEK162, MEK inhibitor; oral
- **DRUG:** Paclitaxel, mitotic inhibitor; intravenous

## Key facts

- **NCT ID:** NCT01649336
- **Lead sponsor:** Array Biopharma, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01649336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01649336, "A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01649336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*